orphanix combines academic expertise in paediatrics with profound research and development know-how. We identify, develop and commercialise innovative medicinal products to solve high unmet medical needs in the paediatric rare disease space. We dive deep into paediatric academia and real-world data to develop the most effective and safe orphan drugs. orphanix is a versatile owner-managed company with an instant access to a pharmaceutical development laboratory. As a development company we complement portfolios of fully integrated pharmaceutical companies with strong sales activities in the paediatric rare disease space.
Our ultimate goal is to improve the lives of paediatric patients with rare diseases. orphanix bridges the gap between existing opportunities and finished pharmaceutical products.
Retinolx for preterm infants
The only medicine under development for preterm infants preventing the life-threatening diseases bronchopulmonary Dysplasia (BPD) and Retinopathy of Prematurity (ROP).
Retinolx fullfills a crucial medical need globally and is backed by four orphan drug designations.